Opinion|Videos|November 4, 2024
Prostate Cancer and Intimacy
Key Takeaways
- Advanced prostate cancer treatment can affect intimacy and QOL, necessitating open communication with healthcare providers.
- Patients should articulate their treatment goals and preferences to influence decision-making and treatment aggressiveness.
Panelists discuss how the diagnosis and treatment of advanced prostate cancer can significantly impact intimacy and relationships, emphasizing the importance of open communication about goals and preferences in treatment decisions, while also sharing strategies for self-advocacy and maintaining quality of life (QOL) throughout the treatment journey.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How can the diagnosis and treatment of advanced prostate cancer affect intimacy for patients? What advice do you offer patients?
- How has your diagnosis and treatment impacted your intimate relationships, and what advice would you give to others?
TOPIC IV: Advocating for Yourself (~5 minutes)
- How important is it for patients to share their goals and preferences in treatment decisions? What role do their preferences play in your treatment decisions, including how aggressive to be?
- How did you speak up for yourself during your treatment journey? What strategies worked for you? What advice would you offer others?
- What should patients consider when talking to their doctors about the risks and benefits of treatments?
- What were your main concerns, and how did you talk about them with your doctor? Do you have any questions that someone going through a similar journey should ask their care team?
- How do QOL issues affect treatment decisions?
- How has your treatment impacted your daily life and overall QOL? Did you have any strategies to help maintain your QOL and continue to be able to do what was important to you?
Advertisement
Related to this article
Learn how nipple-sparing mastectomy, including endoscopic approaches, may help preserve appearance, reduce scarring and support breast cancer recovery.
After 17 and a half years with metastatic primary peritoneal cancer, a former hospital executive explains how an AI health agent helped her after discharge.
Relatives of people with BRCA1 or BRCA2 variants completed genetic testing more often when a navigator reached out directly than when they received a letter.
The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.
Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
Five-year results presented at ASTRO 2026 show a five-week radiation schedule after prostatectomy controls cancer as well as a seven-week course. But serious urinary side effects were more common.
A study of more than 17,000 patients ages 23 to 64, presented at ASTRO 2026, found that only about 28% took endocrine therapy consistently for five years, and people who skipped radiation were more likely to fall off. Here's what to weigh before making that choice.
September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.
Advertisement
Advertisement
Trending on CURE
1
Radiation Oncologist Answers Top Questions About Radiation Therapy
2
FDA Approves Jaypirca as First-Line Treatment for CLL and SLL
3
The Bookends I Needed: Finding Strength in My Brothers After Cancer
4
Giredestrant Combo Cuts Progression Risk by 44% in Advanced Breast Cancer
5